VRDN
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE (VRDN) has 9 SEC Form 4 filings (13 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: May 13, 2026.
Insiders have net bought $20.0M over the trailing 6 months. The largest single insider purchase in this window was $20.0M by Director, 10% Owner Fairmount Funds Management LLC on May 11, 2026.
- Industry:Biotechnology
- CEO:Stephen F. Mahoney
- Employees:252
- HQ:Waltham, MA, US
- IPO:2014-06-18
Insider Buying
$20.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$2.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director, 10% Owner | Purchase | 1,176,470 | $20.0M | May 13 | SEC ↗ |
Related companies
Viridian Therapeutics, Inc.\DE is in the Healthcare sector.